Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stannous Fluoride "Mild" Staining Characterization Sought In Plaque Report

This article was originally published in The Tan Sheet

Executive Summary

Data on the effectiveness of stannous fluoride against gingivitis that minimize the dental staining potential of the ingredient should be included in the final report being prepared by FDA's Dental Products Plaque Subcommittee, Procter & Gamble requests in Nov. 23 comments to the group.

You may also be interested in...



Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR

FDA's advance notice of proposed rulemaking for OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register

Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR

FDA's advance notice of proposed rulemaking for OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register

Zinc Citrate Clinical Data Support Category I Efficacy - Colgate

Data from a double-blind, stratified, six-month clinical study on the efficacy of zinc citrate in reducing plaque and gingivitis supports Category I classification of the ingredient, Colgate-Palmolive states.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel